Tag: tisotumab vedotin-tftv

Home / tisotumab vedotin-tftv

Categories

Tisotumab forvedotin-tftv is approved for recurrent or metastatic cervical cancer

October 2021: The FDA has given tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor combination, rapid approval for adult patients with recurrent ...
tisotumab-vedotin-tftv

Scan the code